Research map: Knowledge and Attitudes on Germline Pharmacogenomic Testing Among Clinical Oncologists

Back to the article

Papers in this map

  1. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network · Mary V. Relling · 2011 · 1182 citations · Cited by this paper
  2. Prediction of Anthracycline Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study · 2026 · Related
  3. An Evidence‐Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine · Michelle Whirl‐Carrillo · 2021 · 830 citations · Cited by this paper
  4. Integrated Radioproteomic Modeling for Early Recurrence Prediction and Metabolic Characterization in Hepatocellular Carcinoma · 2026 · Related
  5. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update · Ursula Amstutz · 2017 · 695 citations · Cited by this paper
  6. Hypoalbuminemia as a Predictive Biomarker of Dyspnea Response to Dexamethasone and Placebo in Patients With Cancer: Secondary Analysis of the ABCD Randomized Clinical Trial · 2026 · Related
  7. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC) · Kelly E. Caudle · 2016 · 572 citations · Cited by this paper
  8. Development and Validation of a Computational Histology Artificial Intelligence–Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials · 2026 · Related
  9. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study · Jesse Joachim Swen · 2023 · 566 citations · Cited by this paper
  10. Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision Study · 2026 · Related
  11. Depression in cancer patients: Pathogenesis, implications and treatment (Review) · H. R. Smith · 2015 · 483 citations · Cited by this paper
  12. Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I · 2026 · Related
  13. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis · Linda M. Henricks · 2018 · 443 citations · Cited by this paper
  14. DNA Damage Response Alterations and Immune Checkpoint Blockade Outcomes Across Multiple Cancers · 2026 · Related
  15. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology · Al B. Benson · 2024 · 369 citations · Cited by this paper
  16. Genomic Landscape of GNAQ and GNA11 Mutations in Metastatic Solid Tumors: A Real-World Data Analysis · 2026 · Related
  17. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines · Carin A.T.C. Lunenburg · 2019 · 241 citations · Cited by this paper
  18. Personalized Molecular Monitoring of a Cryptic DIAPH1::PDGFRB Fusion in Chronic Eosinophilic Leukemia Using Droplet Digital Polymerase Chain Reaction · 2026 · Related
  19. Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology · Patrick Andrew Brown · 2020 · 222 citations · Cited by this paper
  20. Real-World Genomic Characteristics and Prognostic Association in Advanced Papillary Thyroid Carcinoma · 2026 · Related
  21. Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects · Simona Volpi · 2018 · 135 citations · Cited by this paper
  22. PharmGKB summary · Caroline F. Thorn · 2010 · 131 citations · Cited by this paper
  23. Pathogenic DPYD Variants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy: A Systematic Review and Meta-Analysis · Bhavina B. Sharma · 2021 · 93 citations · Cited by this paper
  24. All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide · Federico Innocenti · 2020 · 91 citations · Cited by this paper
  25. Knowledge and attitudes on pharmacogenetics among pediatricians · Shahad Rahawi · 2020 · 75 citations · Cited by this paper
  26. DPYD Genotyping Recommendations · Victoria M. Pratt · 2024 · 63 citations · Cited by this paper
  27. DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice · Forike K. Martens · 2020 · 47 citations · Cited by this paper
  28. Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives · Jai Narendra Patel · 2016 · 45 citations · Cited by this paper
  29. Pediatric pharmacogenomics: challenges and opportunities: on behalf of the Sanford Children’s Genomic Medicine Consortium · David B. Gregornik · 2020 · 45 citations · Cited by this paper
  30. Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation · Kelsey S. Lau‐Min · 2022 · 38 citations · Cited by this paper
  31. Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy · Daniel L. Hertz · 2023 · 34 citations · Cited by this paper
  32. Survey of US Medical Oncologists' Practices and Beliefs Regarding DPYD Testing Before Fluoropyrimidine Chemotherapy · Kyoin Koo · 2022 · 32 citations · Cited by this paper
  33. DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation · Lisa A. Varughese · 2020 · 30 citations · Cited by this paper
  34. A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice · Teresa T. Ho · 2025 · 20 citations · Cited by this paper
  35. The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients · Doreen Zvipo Mhandire · 2022 · 18 citations · Cited by this paper
  36. Healthcare professionals' and consumers' knowledge, attitudes, perspectives, and education needs in oncology pharmacogenomics: A systematic review · Chiao Xin Lim · 2023 · 17 citations · Cited by this paper
  37. Pharmacogenetics testing (DPYD and UGT1A1) for fluoropyrimidine and irinotecan in routine clinical care: Perspectives of medical oncologists and oncology pharmacists · Sarah Glewis · 2023 · 15 citations · Cited by this paper
  38. Design and Implementation of an Opt-Out, End-to-End, Preemptive DPYD Testing Program for Patients Planned for a Systemic Fluoropyrimidine · Joseph O. Jacobson · 2024 · 14 citations · Cited by this paper
  39. Strategies for DPYD testing prior to fluoropyrimidine chemotherapy in the US · Tabea Tracksdorf · 2024 · 9 citations · Cited by this paper

Source: OpenAlex (CC0)